Author Topic: Study, Apr/22:Benzodiazepine use and neuroimaging markers of Alzheimer's disease  (Read 249 times)

[Buddie]

The full title of this French study is "Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort".

https://pubmed.ncbi.nlm.nih.gov/34893757/


Abstract

Recent evidence suggests an association between benzodiazepines (BZDs) use and lower brain amyloid load, a hallmark of AD pathophysiology. Other AD-related markers include hippocampal atrophy, but the effect of BZDs on hippocampal volume remains unclear. We aimed at 1) replicating findings on BZDs use and brain amyloid load and 2) investigating associations between BZDs use and hippocampal volume, in the MEMENTO clinical cohort of nondemented older adults with isolated memory complaint or light cognitive impairment at baseline. Total Standardized Uptake Value Ratio (SUVR) of brain amyloid load and hippocampal volume (HV) were obtained, respectively, from 18F Florbetapir positron emission tomography (PET) and magnetic resonance imaging (MRI), and compared between BZD chronic users and nonusers using multiple linear regressions adjusted for age, sex, educational level, ApoE ε4 genotype, cognitive and neuropsychiatric assessments, history of major depressive episodes and antidepressant intake. BZD users were more likely to manifest symptoms of depression, anxiety and apathy. In the MRI subgroup, BZD users were also more frequently females with low education and greater clinical impairments as assessed with the clinical dementia rating scale. Short- versus long-acting BZDs, Z-drugs versus non-Z-drugs BZDs, as well as dose and duration of BZD use, were also considered in the analyses. Total SUVR and HV were significantly lower and larger, respectively, in BZD users (n = 38 in the PET subgroup and n = 331 in the MRI subgroup) than in nonusers (n = 251 in the PET subgroup and n = 1840 in the MRI subgroup), with a medium (Cohen's d = -0.43) and low (Cohen's d = 0.10) effect size, respectively. Short-acting BZDs and Z-drugs were more significantly associated with larger HV. We found no effect of dose and duration of BZD use. Our results support the involvement of the GABAergic system as a potential target for blocking AD-related pathophysiology, possibly via reduction in neuronal activity and neuroinflammation. Future longitudinal studies may confirm the causal effect of BZDs to block amyloid accumulation and hippocampal atrophy.

2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Conflict of interest statement

TD reports personal fees from Lundbeck, Otsuka and Eisai. GR reports personal fees from Janssen & Janssen and Ostuka. RD reports personal fees from Janssen & Janssen, lundbeck, Lilly, BMS, Servier, Eisai and Biogen. WE reports personal fees from Eisai, Janssen, Lundbeck, Otsuka, UCB, Roche and Chugai. VC reports personal fees from Janssen and Bristol Meyers Squibb. All other authors declare no competing interests. As far as we are aware of, among the pharmaceutical companies mentioned here, only Roche is involved in the production of benzodiazepines (namely diazepam, in its marketed form of Valium in France). Neither Roche nor any of the other pharmaceutical companies mentioned here were consulted regarding the planning or analysis of the study.

Suggestions, opinions and/or advice provided by the author of this post should not be regarded as medical advice; nor should it substitute for professional medical care. Consult your doctor before making any changes to your medication. Please read our Community Policy Documents board for further information.